Gene test predicts odds of postchemotherapy survival among women with breast cancer

Among women with newly diagnosed breast cancer, a predictive test successfully identified those with a high probability of survival following taxane and anthracycline chemotherapy.

As Christos Hatzis, PhD, of Nuvera Biosciences Inc. (Woburn, Massachusetts), and collaborators noted, “Identification of those with significant risk of relapse despite standard chemotherapy could be used to advise participation in an appropriate clinical trial of potentially more effective treatment” (JAMA. 2011;305[18]:1873-1881).

Hatzis's group conducted a 10-year study at the M. D. Anderson Cancer Center to develop and test genomic predictors for neoadjuvant chemotherapy for women with newly diagnosed ERBB2 (HER2 or HER2/neu)-negative breast cancer treated with chemotherapy containing sequential taxane and antrhacycline-based regimens, followed by endocrine therapy if estrogen-receptor [ER]-positive).

The investigators developed different predictive signatures for resistance and response to preoperative chemotherapy using gene expression microarrays from 310 such patients. The test combined ER status, predicted chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity.

The chemopredictive test algorithm had a positive predictive value of 56% for prediction of pathologic response, after excluding women with predicted endocrine sensitivity. Among 28% of participants predicted to be treatment-sensitive, the 3-year distant relapse-free survival (DRFS) rate was 92%.

“Overall, there was a significant association between predicted sensitivity to treatment and improved DRFS,” wrote Hatzis and colleagues.


Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs